Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

429.38 -9.02 (-2.06%)

Streaming Delayed Price Updated: 10:22 AM EDT, Jun 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

74 75 Next >

Key Takeaways From Vertex Pharmaceuticals Analyst Ratings ↗

January 31, 2024

Via Benzinga

Why Vertex Pharmaceuticals Stock Topped the Market Today ↗

January 30, 2024

The company reported that it met its primary endpoint in a study for its non-opioid pain drug.

Via The Motley Fool

Why Is Vertex Pharmaceuticals Stock Sliding Today? ↗

January 30, 2024

Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery.

Via Benzinga

Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst ↗

January 30, 2024

The company unveiled the results of Phase 3 testing in patients following a tummy tuck or bunion removal.

Via Investor's Business Daily

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

January 30, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Here's My Top Growth Stock to Buy Right Now ↗

January 27, 2024

There doesn't appear to be a weak link with this great stock.

Via The Motley Fool

Where Will Vertex Pharmaceuticals Be in 10 Years? ↗

January 25, 2024

As the adage goes, winners keep winning.

Via The Motley Fool

A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings ↗

January 23, 2024

Via Benzinga

Is CRISPR Therapeutics a Buy in the New Bull Market? ↗

January 30, 2024

CRISPR Therapeutics is a specialist in the hot technology of gene editing.

Via The Motley Fool

AI, Biotech, Energy Sectors Expect M&A Revival For 2024 ↗

January 29, 2024

The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.

Via Benzinga

Topics Artificial Intelligence

3 Magnificent Stocks to Buy and Hold Forever ↗

January 27, 2024

Many investors will want to consider owning these stocks for a long time.

Via The Motley Fool

Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? ↗

January 25, 2024

It's always tough to be compared to a giant.

Via The Motley Fool

Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January ↗

January 25, 2024

These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.

Via InvestorPlace

Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts ↗

January 24, 2024

UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.

Via Benzinga

Where Will CRISPR Therapeutics Be in 5 Years? ↗

January 24, 2024

The company could maintain the momentum it gained last year.

Via The Motley Fool

Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 24, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

2 Super Stocks You'll Wish 5 Years From Now That You'd Bought Today ↗

January 24, 2024

These powerhouse stocks still have plenty of growth catalysts to tap into over the coming years.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 23, 2024

Via Benzinga

1 Setback and 1 Opportunity for CRISPR Therapeutics Stock ↗

January 23, 2024

Despite A bump in the road, the biotech's future looks sunny.

Via The Motley Fool

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Via MarketBeat

Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024 ↗

January 22, 2024

Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.

Via Talk Markets

A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist ↗

January 22, 2024

These stocks seem likely to keep up their winning ways.

Via The Motley Fool

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

January 22, 2024

Via Benzinga

If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today ↗

January 22, 2024

Has investing in Vertex been a better option than just putting your money in the S&P 500?

Via The Motley Fool

Topics Stocks

Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks ↗

January 22, 2024

The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase.

Via Investor's Business Daily

Topics ETFs

2 Smart Growth Stocks to Buy Hand Over Fist in 2024 ↗

January 21, 2024

These businesses are on paths to extremely bright futures.

Via The Motley Fool

3 Unstoppable Growth Stocks That Can Make You Richer in 2024 ↗

January 20, 2024

These big winners of 2023 could keep their momentum going in the new year.

Via The Motley Fool

These 2 Phenomenal Growth Stocks Can Make You Richer in 2024 ↗

January 20, 2024

One market-beating stock and one beaten-down stock look like tempting buys for very different reasons.

Via The Motley Fool

3 High-Flying Stocks That Could Soar Even More in 2024 ↗

January 20, 2024

These big winners could keep the momentum going.

Via The Motley Fool

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.